Document is current
Any future updates will be listed below
-
Authors
Arita, Takuto
Suzuki, Shinya
Hirota, Naomi
Yagi, Naoharu
Otsuka, Takayuki
Kobayashi, Hiroaki
Yamashita, Takeshi
Inoue, Hiroshi
,
Atarashi, Hirotsugu
Okumura, Ken
Yamaguchi, Takenori
- License Information
-
More Information
Article History
Received: 31 July 2025
Accepted: 27 January 2026
First Online: 13 February 2026
Declarations
:
: The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and the research protocol was approved by local ethics committees [ , , ]. Information regarding the participating institute was shown in supplementary appendix [ ]. Written informed consent was obtained from all patients. The study was registered in the UMIN Clinical Trials Registry (identifier: UMIN000024006).
: Not applicable.
: Dr Suzuki has received remuneration from Bristol-Myers Squibb and Daiichi Sankyo. Dr Yamashita has received research funding from Daiichi Sankyo Co, Ltd, manuscript fees from Daiichi Sankyo Co, Ltd and Bristol Myers Squibb K.K., and remuneration from Daiichi Sankyo Co, Ltd, Bayer Yakuhin Ltd, Bristol Myers Squibb K.K., Nippon Boehringer Ingelheim Co, Ltd, Novartis, and Ohtsuka Pharmaceutical, Co, Ltd. Dr Inoue has received consultancy fees from Daiichi Sankyo.
